Newsfeeds - Spark Newswire

1 minute read

UPDATE: Sarepta Slide Show Presentation For JP Morgan Healthcare Conference Shows Safety Profile For SRP-9001-102 In Part 2 Trial Was Consistent With Result Seen In Part 1

Today, 7:08 PM

https://jpmorgan.metameetings.net/events/healthcare22/sessions/40550-sarepta-therapeutics-inc/webcast?gpu_only=true&kiosk=true

SRPT

1 minute read

UPDATE: Sarepta Therapeutics Has Released Slides For JP Morgan Conference

By Benzinga Newsdesk

Today, 7:08 PM

https://jpmorgan.metameetings.net/events/healthcare22/sessions/40550-sarepta-therapeutics-inc/webcast?gpu_only=true&kiosk=true

SRPT

1 minute read

Events
News

Sarepta Therapeutics Now Presenting At JP Morgan Conference

By Benzinga Newsdesk

Today, 7:08 PM

https://jpmorgan.metameetings.net/events/healthcare22/general_signin?gpu_only=true

SRPT

1 minute read

10 Biggest Price Target Changes For Wednesday

By Lisa Levin

Today, 7:08 PM

UBS cut the price target for Adobe Inc. (NASDAQ: ADBE) from $635 to $575. Adobe shares fell 2.3% to $541.06 in pre-market trading.

ADBE

1 minute read

Needham Maintains Buy on Sarepta Therapeutics, Lowers Price Target to $150

By Benzinga Newsdesk

Today, 7:08 PM

Needham analyst Gil Blum maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Buy and lowers the price target from $157 to $150.

SRPT

16 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For December 9, 2021

By Benzinga Insights

Today, 7:08 PM

Upgrades According to BMO Capital, the prior rating for Nuvei Corp (NASDAQ:NVEI) was changed from Market Perform to Outperform.

ABBV

1 minute read

JP Morgan Upgrades Sarepta Therapeutics to Overweight, Raises Price Target to $130

By Benzinga Newsdesk

Today, 7:08 PM

JP Morgan analyst Anupam Rama upgrades Sarepta Therapeutics (NASDAQ:SRPT) from Neutral to Overweight and raises the price target from $88 to $130.

SRPT

1 minute read

RBC Capital Maintains Outperform on Sarepta Therapeutics, Lowers Price Target to $145

By Benzinga Newsdesk

Today, 7:08 PM

RBC Capital analyst Brian Abrahams maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and lowers the price target from $148 to $145.

SRPT

1 minute read

Needham Maintains Buy on Sarepta Therapeutics, Lowers Price Target to $157

By Benzinga Newsdesk

Today, 7:08 PM

Needham analyst Gil Blum maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Buy and lowers the price target from $166 to $157.

SRPT

25 minute read

Earnings Scheduled For November 3, 2021

By Benzinga Insights

Today, 7:08 PM

Companies Reporting Before The Bell • R.R.Donnelley & Sons (NYSE:RRD) is likely to report quarterly earnings at $0.32 per share on revenue of $1.19 billion.

AAWW